Jobs
-
Acorda Therapeutics has announced that the PDUFA date for review of its NDA for the Inbrija levodopa DPI for the treatment of symptoms during OFF periods in Parkinson’s disease patients has been changed from October… Read more . . .
-
The FDA has issued dozens of new product-specific draft guidances for generic drug development, including a draft guidance for dry powder formulations of albuterol sulfate. The guidance covers development of generic equivalents to Teva’s ProAir… Read more . . .
-
Mylan said that the company is paying approximately $463 million to Novartis for worldwide rights to TOBI Podhaler tobramycin DPI and TOBI tobramycin inhalation solution. Approximately $240 million of that amount will be paid in… Read more . . .
-
Biohaven Pharmaceuticals said that it has filed an investigational new drug application for its BHV-3500 intranasal calcitonin gene-related peptide (CGRP) receptor antagonist, which it is developing for the prevention and treatment of migraine. BHV-3500, which… Read more . . .
-
Vectura has announced that revenues from inhaled drugs rose 7.1% in the first half of 2018, with Flutiform revenues up 3.1% compared to the first half of 2017 and up 6.1% compared to the second… Read more . . .
-
According to Mundipharma, Napp Pharmaceuticals has launched the company’s Flutiform fluticasone propionate/formoterol fumarate k-haler breath-activated MDI in the UK. The launch is the first in Europe since Flutiform k-haler was approved for the treatment of… Read more . . .
-
Consort Medical subsidiaries Aesica and Bespak will manufacture Opiant Pharmaceuticals’ OPNT003 nalmefene nasal spray, the companies said. Earlier this year, Opiant announced that it would develop OPNT003 for the treatment of opioid overdose using the… Read more . . .
-
Glenmark Pharmaceuticals announced that it has received marketing approval from German authorities for its generic version of Seretide Accuhaler and said that the product will be marketed in Germany as “Salflutin.” The company acquired development… Read more . . .
-
Roivant Sciences has acquired global rights to Patara Pharma’s PA101 cromolyn sodium inhalation solution for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), the company said. The inhalation solution, which will… Read more . . .
-
United Therapeutics will pay MannKind Corporation $45 million up front and up to $50 million in milestone payments, plus potential double-digit royalties for a worldwide exclusive licensing and collaboration agreement for development and commercialization of… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland